FDA approves another Biogen Alzheimer’s drug


The U.S. Food and Drug Administration has approved a second Alzheimer's disease drug made by Biogen Inc. with its Japanese partner, Eisai Inc.

Previous Molecular Lab Partners reports big revenue growth in 2022
Next Top of The List: Nashville's largest assisted-living facilities